Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v3-EN | Version v2-FR | |
|---|---|---|
| Language | English | French |
| Date Updated | 2024-05-02 | 2024-04-04 |
| Drug Identification Number | 02433087 | 02433087 |
| Brand name | MOXIFLOXACIN INJECTION | MOXIFLOXACIN INJECTION |
| Common or Proper name | MOXIFLOXACIN INJECTION | MOXIFLOXACIN INJECTION |
| Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
| Ingredients | MOXIFLOXACIN | MOXIFLOXACIN |
| Strength(s) | 400MG | 400MG |
| Dosage form(s) | SOLUTION | SOLUTION |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
| Packaging size | 250 mL | 250 mL |
| ATC code | J01MA | J01MA |
| ATC description | QUINOLONE ANTIBACTERIALS | QUINOLONE ANTIBACTERIALS |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | 2024-05-01 | 2024-05-01 |
| Actual start date | ||
| Estimated end date | 2024-07-08 | 2024-07-08 |
| Actual end date | ||
| Shortage status | Actual shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Moxifloxacin Injection 1.6 mg/mL freeflex® Bag 250 mL effective May 1, 2024, until July 8, 2024. | Fresenius Kabi Canada regrets to advise that due to production delays, we will be encountering a supply interruption on our Moxifloxacin Injection 1.6 mg/mL freeflex® Bag 250 mL effective May 1, 2024, until July 8, 2024. |
| Health Canada comments |